Apnimed sets $160m IPO for sleep apnea drug

Apnimed sets $160m IPO for sleep apnea drug

Apnimed has filed an S-1 with the US Securities and Exchange Commission (SEC) laying out the terms for its initial public offering (IPO).The Cambridge, Massachusetts-based biotech plans to offer 10 million shares priced between $14 and $16. At the midpoint of that...